Details of Disease

General Information of Disease (ID: DISKFW6V)

• Disease Name: Psychiatric disorder
• Synonyms: mental illness; mental dysfunction; mental disorder; disease of mental health; Psychiatric disorder; Psychiatric disease
• Disease Class: 6E20-6E8Z: Mental/behavioural/neurodevelopmental disorder
• Definition: A disorder characterized by behavioral and/or psychological abnormalities, often accompanied by physical symptoms. The symptoms may cause clinically significant distress or impairment in social and occupational areas of functioning. Representative examples include anxiety disorders, cognitive disorders, mood disorders and schizophrenia.
• Disease Hierarchy:
  DISH7H5I: Human disease
  DISKFW6V: Psychiatric disorder
• ICD Code:
  ICD-11: ICD-11: 6E8Z
  Expand ICD-9: 2.90E+89

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Beclamide	DMJSSGD	Approved	Small molecular drug	[1]
Buprenorphine	DMPRI8G	Approved	Small molecular drug	[2]
Omaveloxolone	DMLMNFX	Approved	Small molecular drug	[3]
Propericiazine	DME9JNL	Approved	Small molecular drug	[4]

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BI-409306	DMJFDS0	Phase 2	NA	[5]
RG7906	DMW2YGQ	Phase 2	Small molecular drug	[6]
ADX71149	DMBUOX4	Phase 1	NA	[7]
BMS-933043	DMG3J6C	Phase 1	NA	[8]
JNJ-42491293	DMOL9JR	Phase 1	NA	[9]
TAK-137	DMYG704	Phase 1	NA	[10]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PLR-21	DMGE84S	Terminated	NA	[11]
SDZ-PSD-958	DM48MCL	Terminated	NA	[12]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SEL-73	DMFKE6C	Investigative	NA	[13]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] ClinicalTrials.gov (NCT02510014) Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder.
• [3] Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin. Arch Dermatol Res. 2014 Jul;306(5):447-54.
• [4] Drug Information of Troleandomycin from nextbio research in illumina. 2015.
• [5] ClinicalTrials.gov (NCT02240693) Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo. U.S. National Institutes of Health.
• [6] Clinical pipeline report, company report or official report of Roche.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030424)
• [8] ClinicalTrials.gov (NCT01605994) Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT01359852) A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers in Healthy Volunteers in Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• [10] ClinicalTrials.gov (NCT02163915) Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder. U.S. National Institutes of Health.
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022821)
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009027)
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 12).